Queen's University at Kingston

🇨🇦Canada

Country: 🇨🇦Canada

Ownership: Private

Established: 1841-10-16

Employees: 1K

Market Cap: -

Website: http://www.queensu.ca

Clinical Trials

Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma

Phase 2

Recruiting

Conditions: Non-hodgkin Lymphoma

Interventions: Drug: Methotrexate
Drug: Rituximab (where available)
Drug: Ibrutinib

First Posted Date: 2023-08-21

Last Posted Date: 2024-11-12

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 30

Registration Number: NCT05998642

Locations: 🇨🇦
The Research Institute of the McGill University, Montreal, Quebec, Canada
🇨🇦
BCCA - Vancouver, Vancouver, British Columbia, Canada
🇨🇦
Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

and more 2 locations

Feasibility of an Interprofessional Rehabilitation Program for Chronic Low Back Patients in the Ethiopian Health Setting

Not Applicable

Not yet recruiting

Conditions: Chronic Low-back Pain

Interventions: Other: Interprofessional rehabilitation program
Other: Usual standard care

First Posted Date: 2023-05-19

Last Posted Date: 2023-05-19

Lead Sponsor: Queen's University

Target Recruit Count: 40

Registration Number: NCT05866146

Magnesium Prophylaxis for the Prevention of New-Onset Atrial Fibrillation in Critically Ill Patients

Phase 4

Recruiting

Conditions: Critical Illness
New Onset Atrial Fibrillation

Interventions: Drug: Placebo
Drug: Magnesium sulfate

First Posted Date: 2023-04-25

Last Posted Date: 2024-11-14

Lead Sponsor: Dr. Stephanie Sibley

Target Recruit Count: 140

Registration Number: NCT05829317

Locations: 🇨🇦
Kingston Health Sciences Centre, Kingston, Ontario, Canada

PembROlizumab With or Without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma

Phase 2

Withdrawn

Conditions: Advanced Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Pembrolizumab
Drug: MET-4
Drug: Placebo

First Posted Date: 2023-02-24

Last Posted Date: 2023-05-18

Lead Sponsor: Canadian Cancer Trials Group

Registration Number: NCT05743777

Neoadjuvant Platform Trial in Non-Small Cell Lung Cancer

Phase 2

Recruiting

Conditions: NSCLC

Interventions: Drug: JDQ443

First Posted Date: 2023-02-06

Last Posted Date: 2024-12-11

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 27

Registration Number: NCT05714891

Locations: 🇨🇦
Verspeeten Family Cancer Centre, London, Ontario, Canada
🇨🇦
University Health Network, Toronto, Ontario, Canada
🇨🇦
CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada

and more 7 locations

Structural Mitral Valve Project

Recruiting

Conditions: Mitral Regurgitation

First Posted Date: 2023-01-10

Last Posted Date: 2023-01-10

Lead Sponsor: Queen's University

Target Recruit Count: 30

Registration Number: NCT05678868

Locations: 🇨🇦
Kingston Health Sciences Centre, Kingston, Ontario, Canada

Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

Phase 2

Recruiting

Conditions: Endometrial Cancer

Interventions: Radiation: Adjuvant radiotherapy (EBRT +/- brachytherapy)
Radiation: Vaginal brachytherapy
Other: Observation

First Posted Date: 2022-12-07

Last Posted Date: 2024-12-11

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 325

Registration Number: NCT05640999

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Duke Womens Cancer Care Raleigh, Raleigh, North Carolina, United States
🇺🇸
Farmington Health Centre, Farmington, Utah, United States

and more 39 locations

RP-6306 in Patients With Advanced Cancer

Phase 2

Recruiting

Conditions: Advanced Cancer

Interventions: Drug: RP-6306
Drug: FOLFIRI Protocol
Drug: Trastuzumab
Drug: RP-3500
Drug: Gemcitabine

First Posted Date: 2022-11-04

Last Posted Date: 2024-12-12

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 78

Registration Number: NCT05605509

Locations: 🇨🇦
Verspeeten Family Cancer Centre, London, Ontario, Canada
🇨🇦
BCCA - Kelowna, Kelowna, British Columbia, Canada
🇨🇦
BCCA - Vancouver, Vancouver, British Columbia, Canada

and more 4 locations

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

Phase 2

Recruiting

Conditions: Breast Cancer

Interventions: Other: Observation
Drug: RP-6306
Drug: Niraparib
Drug: Gemcitabine
Drug: Fulvestrant
Drug: RP-3500

First Posted Date: 2022-11-01

Last Posted Date: 2024-12-18

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 484

Registration Number: NCT05601440

Locations: 🇨🇦
The Jewish General Hospital, Montreal, Quebec, Canada
🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
🇨🇦
BCCA - Kelowna, Kelowna, British Columbia, Canada

and more 7 locations

Be Outspoken and Overcome Stigmatizing Thoughts (BOOST) Group for Early Psychosis

Not Applicable

Active, not recruiting

Conditions: Schizophrenia
Psychosis

Interventions: Behavioral: Self-stigma intervention

First Posted Date: 2022-10-07

Last Posted Date: 2023-11-15

Lead Sponsor: Queen's University

Target Recruit Count: 100

Registration Number: NCT05571228

Locations: 🇨🇦
Queen's University, Kingston, Ontario, Canada

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy